A PD study has shown no statistically significant difference in pulmonary artery pressure effects of Levadex inhaled dihydroergotamine (DHE) compared to placebo, according to MAP Pharmaceutical. The inhaled formulation had a smaller effect on pulmonary artery pressure than IV DHE. MAP has said that it intends to submit an NDA for Levadex for the treatment of migraine in the first six months of 2011. Read the company’s
